A new study from the University of Helsinki shows that cells that are freshly isolated from lung cancers can be used to create robust drug response data. This approach can identify actionable or non-responsive treatments, illustrated by a case study in which the assay was used to guide the compassionate treatment of a patient.
Each cancer tissue is unique, complicating treatment decisions. The power of precision medicine to match treatments to an individual patient is therefore evident. Yet, its actual success in the clinic has remained limited, particularly for solid tumors.